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Editorial on the Research Topic
Non-Infectious Complications of Primary Antibody Deficiency
Primary antibody deficiencies represent by far the largest group of primary immunodeficiencies
(PID) at 56% (ESID Registry), however the proportion of patients in whom antibody deficiency
represents a component of their condition is greater still at around 75% (1). It has become clear over
recent years that while the vast majority of such patients experience recurrent infections a significant
proportion are also affected by non-infectious dysregulatory complications which include
malignancy, autoimmunity, inflammation and allergy (Figure 1). The increasingly complex
manifestations of Primary Antibody Deficiencies have a major impact on the clinical
management of patients and raise diagnostic and therapeutic challenges (2). This Research Topic
draws together a series of reports focusing on a range of these non-infectious complications and
their clinical implications.GENETICS
In recent years, our understanding of genetics of primary antibody deficiencies (PAD) (1) further
progressed unraveling an independent role of minor and major histocompatibility complex genes
and common genetic variants as well as monogenic forms as shown by Abolhassani et al. who
identified the most significant partial haplotype linked with the unsolved CVID as W*01:01:01-
DMA*01:01:01-DMB*01:03:01:02-TAP1*01:01:01. Beside the high number of BTKmutations so far
described (2), some atypical clinical manifestations have been described in XLA patients and linked
to a novel hemizygous c.1632-1G>Amutation in the BTK gene as shown by Han et al. in a child with
atypical X-Linked Agammaglobulinemia and recurrent hemophagocytosis (HLH) whose remission
of HLH episodes was finally achieved after he received monthly Ig replacement therapy as the only
treatment for HLH.org April 2021 | Volume 12 | Article 6354821
FIGURE 1 | The complexity of Primary Antibody Deficiencies.
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As outlined, further advances in understanding key aspects of primary
antibody deficiency associated conditions should assist in advances in
diagnosis and management. New aspects of the clinical complexity of
PAD was reported by Coopmans et al. who suggested that an
assessment of the endocrine axis should be considered since a high
prevalence of both anterior pituitary and end-organ endocrine
dysfunction (secondary hypothyroidism, secondary hypogonadism,
premature ovarian failure, primary testicular failure, partial adrenal
insufficiency, severe growth or mild hormone deficiency) were
identified in adult PAD patients causing a considerable health
burden. A detailed description of CVID-associated non-infectious
complication was reported by Ho and Cunningham-Rundles.
Autoimmunity, chronic lung disease, lymphoid hyperplasia/
splenomegaly, liver disease, granulomas, gastrointestinal disease,
lymphoma and other malignancies were found in two third of
CVID patients. These complications may be present in the same
patient, and progress to a wide spectrum of associated sequelae. An
aggressive multidisciplinary approach may reduce such progression.
Further exacerbations, as for permanent lung damage and
bronchiectasis, may develop even in the absence of known
infections, as shown by Wall et al. Similarly, in the liver, granulomasFrontiers in Immunology | www.frontiersin.org 2and nodular regenerative hyperplasia progressing to portal
hypertension (3) affected about 50% of CVID patients without or
withmonogenic forms included in the clinical spectrum of CVID such
as ICOS, NFKB1, NFKB2, CTLA-4, PI3Kd pathway, ADA2, and
IL21-R genetic defects, as shown by Antonio Pecoraro et al.
PATHOGENESIS
The hallmarks of CVID are hypogammaglobulinemia, low
frequency of isotype-switched memory B cells, and compromised
B-cell differentiation into memory or antibody-secreting cells (4).
Further insight on cellular defects underlying CVID pathogenesis
are illustrated by Carsetti et al. who showed that circulating IgM
memory B cells have a distinctive role in mucosal protection and
suggested the existence of a functional gut-spleen axis where TACI-
expressing IgMmemory B cells producing IgA were localized under
the epithelial cell layer where the TACI ligand APRIL was extremely
abundant. The impairment of mucosal immunity might result in
less diverse and significantly altered bacterial, but not fungal gut
microbiota, in CVID patients, apparently associated with a more
severe disease phenotype as shown by Fiedorová et al. Although
described as a B cell intrinsic disease, numerous abnormalities have
been reported in other immune cell compartments as in follicularApril 2021 | Volume 12 | Article 635482
Quinti et al. Editorial: Primary Antibody Deficiencieshelper T cells, a CD4+ T cell population specialized in B cell help as
described by Le Saos-Patrinos et al., and by Gereige and Maglione
who address the aspects of immune dysregulation associated with
autoimmunity, including elevations of T helper type 1 and follicular
helper T cells and B cells expressing low levels of CD21 as well as a
decrease in regulatory T cells.DIAGNOSIS
An often unresolved aspect in the management of antibody
deficiencies is the differential diagnosis with secondary forms of
hypogammaglobulimias, and in particular those associated with
lymphoproliferative diseases (5). Scarpa at al. proposed that serum
free light chains analysis might have a role in differential diagnosis of
CVID from other causes of hypogammaglobulinemia and in the
early detection of monoclonal lymphoproliferation occurring over
years. Overall, CVID patients presented a low k and l chain
concentration. The most common pattern was k−l−, followed by
k−l+, k+l+, and k+l−, while in secondary forms it was k+l+.CONTROVERSIES
Experience of solid organ transplantations, and hematopoietic
stem cell transplantation in patients with primary antibodyFrontiers in Immunology | www.frontiersin.org 3deficiency remains limited and this aspect of management
needs further study alongside the developing potential of gene
therapy and gene editing.CONCLUSIONS
Together the articles comprising this Research Topic provide
important and timely updates about the current status of non-
infectious diseases in primary antibody deficiencies, and in
particular in CVID. Each report raises questions and indicates
aspects that require further attention and scientific enquiry.AUTHOR CONTRIBUTIONS
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